NCT01534637: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer |
|
|
| Completed | 2 | 22 | US | aprepitant, Emend, L-754030, MK-0869, ONO-7436, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, capecitabine, CAPE, Ro 09-1978/000, Xeloda, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, radiation therapy, irradiation, radiotherapy, therapy, radiation, questionnaire administration, quality-of-life assessment, quality of life assessment, nausea and vomiting therapy, antiemetic support, management of nausea and vomiting, nausea and vomiting management, therapy, nausea and vomiting, vomiting and nausea management, management of therapy complications, complications of therapy, management of | Wake Forest University Health Sciences, National Cancer Institute (NCI), Merck Sharp & Dohme LLC | Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer | 12/09 | 08/12 | | |
